Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Ryzodeg

02 7Tresiba

03 6Xultophy

PharmaCompass

01

Brand Name : Ryzodeg

Insulin Degludec

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ryzodeg

arrow
2024 ACI Convention
Not Confirmed

Insulin Degludec

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 210

2019 Revenue in Millions : 162

Growth (%) : 30

blank

02

Brand Name : Xultophy

Insulin Degludec

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xultophy

arrow
2024 ACI Convention
Not Confirmed

Insulin Degludec

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 398

2019 Revenue in Millions : 359

Growth (%) : 11

blank

03

Brand Name : Tresiba

Insulin Degludec

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tresiba

arrow
2024 ACI Convention
Not Confirmed

Insulin Degludec

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 1,459

2019 Revenue in Millions : 1,506

Growth (%) : -3

blank

04

Brand Name : Xultophy

Insulin Degludec

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xultophy

arrow
2024 ACI Convention
Not Confirmed

Insulin Degludec

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 405

2020 Revenue in Millions : 391

Growth (%) : 9

blank

05

Brand Name : Tresiba

Insulin Degludec

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tresiba

arrow
2024 ACI Convention
Not Confirmed

Insulin Degludec

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 1,483

2020 Revenue in Millions : 1,435

Growth (%) : 8

blank

06

Brand Name : Ryzodeg

Insulin Degludec

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ryzodeg

arrow
2024 ACI Convention
Not Confirmed

Insulin Degludec

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 261

2020 Revenue in Millions : 207

Growth (%) : 33

blank

07

Brand Name : Xultophy

Insulin Degludec

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xultophy

arrow
2024 ACI Convention
Not Confirmed

Insulin Degludec

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 410

2021 Revenue in Millions : 405

Growth (%) : 1

blank

08

Brand Name : Ryzodeg

Insulin Degludec

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ryzodeg

arrow
2024 ACI Convention
Not Confirmed

Insulin Degludec

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 421

2021 Revenue in Millions : 261

Growth (%) : 62

blank

09

Brand Name : Tresiba

Insulin Degludec

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tresiba

arrow
2024 ACI Convention
Not Confirmed

Insulin Degludec

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 1,364

2021 Revenue in Millions : 1,483

Growth (%) : -8

blank

10

Brand Name : Xultophy

Insulin Degludec

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Xultophy

arrow
2024 ACI Convention
Not Confirmed

Insulin Degludec

Main Therapeutic Indication : Diabetes

Currency : USD

2023 Revenue in Millions : 468

2022 Revenue in Millions : 410

Growth (%) : 15

blank